logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Institut Curie Hospital

+33156245500
elise.dumas@curie.fr
Source: Site record.
http://www.curie.fr

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

Institut Curie, a leading institution in the fight against cancer, combines an internationally renowned Research Center with a state-of-the-art Hospital Group that treats all types of cancer, including the rarest forms.Founded in 1909 by Marie Curie, Institut Curie brings together more than 3,300 researchers, doctors, and healthcare professionals across three sites (Paris, Saint-Cloud, and Orsay), focusing on three core missions: research, patient care, and the preservation and transmission of knowledge.As a private foundation recognized as serving the public interest and authorized to receive donations and bequests, Institut Curie is able, thanks to the support of its donors, to advance scientific discoveries and thereby improve treatments and the quality of life of patients.

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. Cancer treatment center

Business Subcategory

Source: Human-provided. Cancer treatment center
Source: Trial-derived.
53Total Trials
Source: Trial-derived.
12Recruiting Trials
Source: Trial-derived.
18Active Trials
Source: Trial-derived.
1Completed Trials
Source: Trial-derived.
77Unique Conditions
Source: Trial-derived.
67Unique Sponsors

Conditions

Source: Trial-derived. Breast Cancer (3)Source: Trial-derived. Cancer (3)Source: Trial-derived. Neuroblastoma (3)Source: Trial-derived. Non-small Cell Lung Cancer (3)Source: Trial-derived. Ovarian Cancer (3)Source: Trial-derived. Solid Tumors (3)Source: Trial-derived. Osteosarcoma (2)Source: Trial-derived. Solid Tumors Harboring NTRK Fusion (2)

Sponsors

Source: Trial-derived. Hoffmann-La Roche (8)Source: Trial-derived. Institut Curie (6)Source: Trial-derived. EMD Serono Research & Development Institute, Inc. (5)Source: Trial-derived. Merck KGaA, Darmstadt, Germany (5)Source: Trial-derived. ARCAGY/ GINECO GROUP (4)Source: Trial-derived. Bayer (4)Source: Trial-derived. Bristol-Myers Squibb (3)Source: Trial-derived. ETOP IBCSG Partners Foundation (3)

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Echocardiography
Source: AI-inferred. Electrocardiography (lead count not stated)

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Amenities

Amenities Available

Source: Google. Restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Tumour molecular mutation testing